Hypertension; Treatment; low-dose combination treatment; Traitement; Association thérapeutique faiblement dosée
Abstract :
[en] If the treatment of hypertension is very useful to decrease the cardiovascular risk, the way to get the normalisation of high blood pressure is difficult in spite of many families of antihypertensive agents with different mechanisms of action. To reach such objective, association of different drugs are most often required. But, the european guidelines for the management of hypertension have just been released and proposed the possibility to begin very-low-dose combination therapy first-line. These associations offer immediate higher efficacy, excellent tolerance and low cost. [fr] Si le traitement de l’hypertension artérielle est très rentable en terme de réduction du risque cardio-vasculaire, la manière de normaliser l’élévation de pression reste une entreprise difficile et ce malgré la mise à la disposition de nombreuses familles d’agents antihypertenseurs. Pour atteindre ce but, il faut bien souvent recourir à des associations de molécules de familles différentes.
L'utilisation d’emblée de telles associations mais à posologies très faibles vient d’être proposée par les nouvelles directives européennes du traitement de l’hypertension. Ces associations très faiblement dosées apportent une nouvelle dimension dans les schémas de traitement en tentant d’être rapidement efficace chez un plus grand nombre d’hypertendus avec un minimum d’effets secondaires. Un rapport coût/ efficacité faible est aussi un avantage.
Disciplines :
General & internal medicine Urology & nephrology
Author, co-author :
Krzesinski, Jean-Marie ; Université de Liège - ULiège > Département des sciences cliniques > Néphrologie
Rorive, Marcelle ; Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques
Language :
French
Title :
Y a-t-il une place d'emblée pour une bithérapie faiblement dosée dans le traitement de l'hypertension artérielle essentielle?
Alternative titles :
[en] Is there any interest in using very-low combination therapy in the first-line approach to hypertension treatment?
Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53.
Krzesinski JM. Qualité de la prise en charge de l'hypertension artérielle. Pouvons-nous, devons-nous faire mieux. Rev Med Liège 2002; 57: 202-6.
Hyman D, Pavlick V. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 2001; 345: 479-86.
Mallion JM, Schmitt D. Patient compliance in the treatment of arterial hypertension. J Hypertens 2001; 19: 2281-3.
Rorive G, Godon E. Le suivi du traitement: tendon d'Achille de la thérapeutique antihypertensive. Med Hyg 1999; 57: 1538-40.
Waeber B, Brunner H. Main objectives and new aspects of combination treatment of hypertension. J Hypertens 1995; 13 (Suppl. 2): 15S-9S.
Dickerson JEC, Hingorani A, Ashby M, Palmer C, Brown M. Optimisation of antihypertensive treatment by cross-over rotation of four major classes. Lancet 1999; 353: 2008-13.
Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62.
Waeber B, Brunner HR. Rationale for the use of very-low-dose combinations as first-line treatment of hypertension. J Hypertens 2001; 19 (Suppl. 4): 3S-8S.
Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents, A systematic review and meta-analysis. JAMA 1997; 277: 739-45.
Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: A network meta-analysis. JAMA 2003; 289: 2534-44.
Prisant M. Fixed lowdose combination in first-fine treatment of hypertension. J Hypertens 2002; 20 (Suppl. 1): 11S-9S.
Frishman WH, Bruyzinski BS, Coulson LR, et al. A multifactorial trial disgn to assess combination therapy in hypertension. Treatment with bisoprolol and hydrochlorothiazide. Arch Int Med 1994; 154: 1461-8.
Weir M, Prisant M, Papademetriou V, et al. Antihypertensive therapy and quality of life, influence of blood pressure reduction, adverse events and prior antihypertensive therapy. AJH 1996; 9: 854-9.
Benetos A, Adamopoulos C, Argyriadis P, Bean K, Consoli S, Safar M. Clinical results with bisoprolol 2,5 mg/hydrochlorothiazide 6,25 mg combination in systolic hypertension in the elderly. J Hypertens 2002; 20 (Suppl. 1): 21S-5S.
Myers M, Asmar R, Leenen F, Safar M. Fixed low-dose combination therapy in hypertension - a dose response study of perindopril an dindapamide. J hypertens 2000; 18: 317-25.
Chalmers J, Castaigne A, Morgan T, Chastang C. Long-term efficacy of a new, fixed, very-low-dose angiotensin-converting enzyme-inhibitor/diuretic combination as first-line therapy in elderly hypertensive patients. J Hypertension 2000; 18: 327-37.
Laurent S. Clinical benefit of very low-dose perindopril-indapamide combination in hypertension. J Hypertens 2001; 19 (Suppl. 4): 9S-14S.
Asmar RG, London GM, O'Rourke ME, et al. Amelioration of arterial properties with a perindopril-indapamide very-low-dose combination. J Hypertens 2001; 19 (Suppl. 4): 15S-20S.
Ruzicka M, Leenen F. Monotherapy versus combination therapy as first line treatment of uncomplicated arterial hypertension. Drugs 2001; 61: 943-54.
Berlowitz D, Ash A, Hickey E, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998; 339: 1957-63.
Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, Evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA 2003; 289: 2560-71.
Laurent S. Very-low-dose combination of perindopril and indapamide: Efficacy on blood pressure and target-organ disease. J Hypertens 2003; 1 ((Suppl. 3): 11S-8S.
Ambrosioni E. Healthcare benefits of very-low-dose combination treatment used in the management of hypertension. J Hypertens 2001; 19 (Suppl. 4): 29S-36S.
